Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
44 Results for "
CTGF
" in MedChemExpress (MCE) Product Catalog:
Products (44)
44 Results for "CTGF" in MCE Product Catalog:
2
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Ramipril (HOE-498) is an orally active angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, and it is metabolized in vivo to the active metabolite Ramiprilat (HY-A0115). Ramipril has antioxidant, vasoprotective, and anti-atherosclerotic effects. Ramipril reduces the degradation of angiotensin II and bradykinin, downregulates TGF-beta/CTGF/fibronectin/α-SMA, and inhibits pancreatic/cardiac fibrosis. Ramipril improves glucose tolerance and insulin secretion, and reduces weight gain/appetite. Ramipril sensitizes mast cells, enhances FcεRI histamine release/degranulation, aggravates IgE allergic reactions, and downregulates the bradykinin receptor. Ramipril improves vascular endothelial relaxation function in spontaneously hypertensive rats. Ramipril alleviates Oxaliplatin (HY-17371)-induced acute hyperalgesia in mice. Ramipril can be used in research related to diseases such as type 2 diabetes, rheumatoid arthritis, allergy, and hypertension .
2
2 Cited Publications
Cat. No.: HY-P99288
CAS No.: 946415-13-0
Synonyms: Pamrevlumab; Anti-Human CTGF Recombinant Antibody
Target:
Research Areas:
2
2 Cited Publications
Cat. No.: HY-P72153
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CCN2; CCN Family Member 2; Prev. CTGF; IBP-8; IGFBP8; SEMDLSL; Connective Tissue Growth Factor; IGFBP-8; Hypertrophic Chondrocyte-Specific Protein 24; NOV2; Insulin-Like Growth Factor-Binding Protein 8; KMD; IGF-Binding Protein 8; Cellular Communication N
Species:
Human
Source:
E. coli
2
2 Cited Publications
Cat. No.: HY-P72154
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CCN2; CCN Family Member 2; Prev. CTGF; IBP-8; IGFBP8; SEMDLSL; Connective Tissue Growth Factor; IGFBP-8; Hypertrophic Chondrocyte-Specific Protein 24; NOV2; Insulin-Like Growth Factor-Binding Protein 8; KMD; IGF-Binding Protein 8; Cellular Communication N
Species:
Mouse
Source:
E. coli
1
1 Cited Publications
Target:
Research Areas:
(rel)-AR234960 is a selective and competitive agonist of the G protein-coupled receptor MAS. (rel)-AR234960 binds to the MAS receptor to activate the downstream ERK1/2 signaling pathway, inducing the expression of connective tissue growth factor (CTGF) and its downstream collagen subtype genes (such as COL1A1, COL3A1). (rel)-AR234960 promotes collagen synthesis in cardiac fibroblasts through the MAS-ERK1/2-CTGF pathway and aggravates extracellular matrix remodeling. (rel)-AR234960's in vitro effect can be blocked by the MAS inverse agonist AR244555 and MEK1 inhibitor. (rel)-AR234960 regulates the expression of cardiac fibrosis-related genes and can be used in the study of heart failure .
1
1 Cited Publications
Cat. No.: HY-P70602
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CCN2; CCN Family Member 2; Prev. CTGF; IBP-8; IGFBP8; SEMDLSL; Connective Tissue Growth Factor; IGFBP-8; Hypertrophic Chondrocyte-Specific Protein 24; NOV2; Insulin-Like Growth Factor-Binding Protein 8; KMD; IGF-Binding Protein 8; Cellular Communication N
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P78104
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: CCN2; CCN Family Member 2; Prev. CTGF; IBP-8; IGFBP8; SEMDLSL; Connective Tissue Growth Factor; IGFBP-8; Hypertrophic Chondrocyte-Specific Protein 24; NOV2; Insulin-Like Growth Factor-Binding Protein 8; KMD; IGF-Binding Protein 8; Cellular Communication N
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P79369
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CCN2; CCN Family Member 2; Prev. CTGF; IBP-8; IGFBP8; SEMDLSL; Connective Tissue Growth Factor; IGFBP-8; Hypertrophic Chondrocyte-Specific Protein 24; NOV2; Insulin-Like Growth Factor-Binding Protein 8; KMD; IGF-Binding Protein 8; Cellular Communication N
Species:
Rat
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P70106
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CCN2; CCN Family Member 2; Prev. CTGF; IBP-8; IGFBP8; SEMDLSL; Connective Tissue Growth Factor; IGFBP-8; Hypertrophic Chondrocyte-Specific Protein 24; NOV2; Insulin-Like Growth Factor-Binding Protein 8; KMD; IGF-Binding Protein 8; Cellular Communication N
Species:
Human
Source:
HEK293
1
1 Cited Publications
Cat. No.: HY-P81103
Synonyms: CCN 2; CCN-2; CCN2; Connective Tissue Growth Factor; Hcs 24; Hcs24; Hypertrophic chondrocyte specific protein 24; Hypertrophic chondrocyte-specific gene product 24; Insulin-like Growth Factor-Binding Protein 8; MGC102839; NOV 2; NOV2; Connective tissue growth factor; CCN family member 2; Hypertrophic chondrocyte-specific protein 24; Insulin-like growth-binding protein 8; IBP-8; IGF-binding protein 8; IGFBP8; IGFBP-8; connective tissue growth factor precursor; CTGF_HUMAN.
PROTAC TEAD degrader-1 is a TEAD2 degrader and antiproliferative agent with selective activity toward TEAD2 relative to other TEAD family members. PROTAC TEAD degrader-1 relies on CRBN and the proteasome system for TEAD2 degradation; disruption of CRBN binding attenuates this activity. PROTAC TEAD degrader-1 decreases expression of YAP target genes CYR61 and CTGF. PROTAC TEAD degrader-1 can be used for the research of NF2-deficient cancer .
Research Areas:
PRX-08066 is a selective and orally active 5-hydroxytryptamine receptor 2B (5-HT2BR) antagonist with a Ki of 3.4 nM. PRX-08066 inhibits the MAPK pathway, 5-HT release and fibrotic factor (TGFβ1, CTGF and FGF2) expression. PRX-08066 inhibits the proliferation of KRJ-I cells and induces apoptosis (caspase-3 activation). PRX-08066 inhibits pulmonary vascular remodeling. PRX-08066 can be used of pulmonary Arterial Hypertension (PAH) and neuroendocrine tumor (NET) .
Cat. No.: HY-B0279S
CAS No.: 1132661-86-9
Synonyms: HOE-498-d5
Ramipril-d5 (HOE-498-d5) is the deuterated-labeled Ramipril (HY-B0279). Ramipril (HOE-498) is an orally active angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, and it is metabolized in vivo to the active metabolite Ramiprilat (HY-A0115). Ramipril has antioxidant, vasoprotective, and anti-atherosclerotic effects. Ramipril reduces the degradation of angiotensin II and bradykinin, downregulates TGF-beta/CTGF/fibronectin/α-SMA, and inhibits pancreatic/cardiac fibrosis. Ramipril improves glucose tolerance and insulin secretion, and reduces weight gain/appetite. Ramipril sensitizes mast cells, enhances FcεRI histamine release/degranulation, aggravates IgE allergic reactions, and downregulates the bradykinin receptor. Ramipril improves vascular endothelial relaxation function in spontaneously hypertensive rats. Ramipril alleviates Oxaliplatin (HY-17371)-induced acute hyperalgesia in mice. Ramipril can be used in research related to diseases such as type 2 diabetes, rheumatoid arthritis, allergy, and hypertension .
Cat. No.: HY-N0136B
CAS No.: 111003-33-9
Synonyms: (-)-Dihydroquercetin
Cat. No.: HY-179505
CAS No.: 2866423-35-8
OPN-9652 is a potent, orally active, and covalent TEAD inhibitor (MSTO-211H TEAD IC50 = 0.005 µM) targeting the central palmitate binding pocket of TEADs. OPN-9652 reduces TEAD-dependent reporter activity and expression of TEAD targets (CTGF and CYR61). OPN-9652 resensitizes drug-tolerant SOX10 KO cells to BRAFi + MAPKi. OPN-9652 delays the onset of tumor resistance to BRAFi + MEKi from minimal residual disease (MRD) in a BRAF mutant A375 xenograft mouse model. OPN-9652 can be used for melanoma research .
Cat. No.: HY-B0279S1
CAS No.: 2673269-81-1
Synonyms: HOE-498-d3
Ramipril-d3 (HOE-498-d3) is the deuterated-labeled Ramipril (HY-B0279). Ramipril (HOE-498) is an orally active angiotensin-converting enzyme (ACE) inhibitor with blood-brain barrier permeability, and it is metabolized in vivo to the active metabolite Ramiprilat (HY-A0115). Ramipril has antioxidant, vasoprotective, and anti-atherosclerotic effects. Ramipril reduces the degradation of angiotensin II and bradykinin, downregulates TGF-beta/CTGF/fibronectin/α-SMA, and inhibits pancreatic/cardiac fibrosis. Ramipril improves glucose tolerance and insulin secretion, and reduces weight gain/appetite. Ramipril sensitizes mast cells, enhances FcεRI histamine release/degranulation, aggravates IgE allergic reactions, and downregulates the bradykinin receptor. Ramipril improves vascular endothelial relaxation function in spontaneously hypertensive rats. Ramipril alleviates Oxaliplatin (HY-17371)-induced acute hyperalgesia in mice. Ramipril can be used in research related to diseases such as type 2 diabetes, rheumatoid arthritis, allergy, and hypertension .
Cat. No.: HY-120409
CAS No.: 1463912-49-3
Target:
Research Areas:
AB1 is a highly selective S1P2 receptor antagonist (IC50=3.5 nM). AB1 inhibits sphingosine-1-phosphate (S1P) signaling, suppressing tumor cell migration, angiogenesis, and profibrotic mediator CTGF expression while inducing apoptosis. AB1 is promising for research of solid tumors .
Cat. No.: HY-179440
EA-C15 is a potent and selective TEAD inhibitor with an IC50 of 0.34 μM. EA-C15 covalently binds to the TEAD palmitoylation site, blocks palmitoylation and transcriptional activity, and inhibits YAP-dependent cancer cell proliferation and YAP-TEAD target gene (CTGF and CYR61) transcription. EA-C15 can be used for cancer research .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
